43
Participants
Start Date
November 30, 2009
Primary Completion Date
March 31, 2013
Study Completion Date
June 30, 2015
YM155
intravenous infusion
Rituximab
intravenous infusion
Site US9 Mount Sinai School of Medicine, New York
Site ES1339 Hospital Universitario Ramon y Cajal, Madrid
Site ES2967 Hosptial Universitario Madrid Sanchinarro, Madrid
Site US2802 Mecklenburg Medical Group, Charlotte
Site US2778 John B. Amos Cancer Center, Columbus
Site FR1926 Institut Bergonie, Bordeaux
Site ES1346 Hospital Universitario de Salamanca, Salamanca
Site FR1897 Hopital Bretonneau, Tours
Site US2149 Gabrail Cancer Center Research, Canton
Site US55 Loyola University Hospital - Maywood, Maywood
Site FR476 Hopital Saint Louis, Paris
Site FR1889 Centre de Lutte Contre le Cancer - Centre Henri Becquerel, Rouen
Site US402 University of Texas Health Science Center - San Antonio, San Antonio
Site FR2700 Centre Antoine Lacassagne, Nice
Site ES1349 Hospital del Mar, Barcelona
Site GB2702 Addenbrookes Hospital, Cambridge
Site GB1928 St. Georges Hospital, London
Site GB2624 The Christie NHS Foundation Trust, Manchester
Site GB1903 Oxford Radcliffe Hospital, Oxford
Lead Sponsor
Astellas Pharma Inc
INDUSTRY